title: Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
abstract: In a randomized open controlled study the clinical effects and tolerability of prostaglandin E1 (PGE1) and the stable prostacyclin (PGI2) analogue, iloprost in the management of diabetic and non-diabetic patients with advanced peripheral arterial occlusive disease (PAOD Fontaine stage IV) were compared. 267 patients were enrolled in this multicentre study and treated for 21-28 days, either by daily infusions of 6 h with iloprost or 2 x 2 h with PGE1. At the end of treatment patients were assessed for evidence of improvement of trophic lesions, relief of rest pain and change of global clinical status. 228 patients were considered as evaluable for efficacy analysis, which revealed 52.7% responders in the iloprost group and 43.1% for PGE1 (p = 0.148). Whereas iloprost showed similar effects in diabetics and non-diabetics (53.3% and 51.4% response rates, respectively), the diabetics treated with PGE1 had a considerably poorer outcome (36.6% versus 53.3%). At 6 months follow-up 62.2% of patients in both groups were alive with a viable limb. Slightly more iloprost patients underwent major amputation (32.1% versus 27.2%), but the number of deaths was reduced by 50% in the iloprost group compared to the PGE1 group (7.5% versus 14.6%, p = 0.10). Side-effects such as headache, flushing and gastrointestinal symptoms were significantly more common in the iloprost group (73.9%) than in the PGE1 group (31.0%), particularly during the first 3 days of dose titration. No specific toxic or unexpected reactions were reported in either group.
authors.affiliation: Schering AG, Berlin, Germany.
authors.forename: H O
authors.initials: HO
authors.lastname: Altstaedt
authors.forename: B
authors.initials: B
authors.lastname: Berzewski
authors.forename: H K
authors.initials: HK
authors.lastname: Breddin
authors.forename: W
authors.initials: W
authors.lastname: Brockhaus
authors.forename: H D
authors.initials: HD
authors.lastname: Bruhn
authors.forename: M
authors.initials: M
authors.lastname: Cachovan
authors.forename: C
authors.initials: C
authors.lastname: Diehm
authors.forename: J
authors.initials: J
authors.lastname: Dörrler
authors.forename: C S
authors.initials: CS
authors.lastname: Franke
authors.forename: J D
authors.initials: JD
authors.lastname: Gruss
mesh_terms: D000328:Adult; D000368:Aged; D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy; D003925:Diabetic Angiopathies / Q000188:drug therapy; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D016285:Iloprost / Q000008:administration & dosage / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*
chemical_list: D000527:Alprostadil; D016285:Iloprost